Sanofi’s innovative targeted nanobody drug, Kebeli, has been approved in China.
November 6, 2025
Source: drugdu
73
On November 5th, SanofiAnnouncement of its innovative drugCablivi (caracizumab for injection) has been officially approved by the National Medical Products Administration (NMPA) for use in combination with plasma exchange and immunosuppressive therapy.Acquired thrombotic thrombocytopenic purpura (aTTP, also known as immune-mediated thrombotic thrombocytopenic purpura) in adults and adolescents aged 12 years and older weighing at least 40 kg.
https://finance.eastmoney.com/a/202511053556137255.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
